

Clinical trials of SR123781A

TrialResults-center www.trialresultscenter.org

1 DVT prophylaxis

Trial	Treatments	Patients	Trials design and methods
SR123781A vs enoxaparin			
DRIVE , 2008 [NCT00338897] n=854/169 follow-up: 5-10 days	SR123781A for 5-10 days, doses ranging from 0.25 to 4.0 mg daily for 10 days versus enoxaparin 40 mg	patients undergoing total hip replacement surgery	Parallel groups double blind 12 countries

More details and results :

- antithrombotics for DVT prophylaxis in orthopedic surgery at <http://www.trialresultscenter.org/go-Q37>
- antithrombotics for DVT prophylaxis in elective hip replacement at <http://www.trialresultscenter.org/go-Q39>
- pentasaccharide for DVT prophylaxis in orthopedic surgery at <http://www.trialresultscenter.org/go-Q188>
- pentasaccharide for DVT prophylaxis in all type of patients at <http://www.trialresultscenter.org/go-Q396>

References

DRIVE, 2008:

Lassen MR, Dahl O, Mismetti P, Zieske D, Turpie AG SR123781A: a new once-daily synthetic oligosaccharide anticoagulant for thromboprophylaxis after total hip replacement surgery: the DRIVE (Dose Ranging Study in Elective Total Hip Replacement Surgery) study. J Am Coll Cardiol 2008 Apr 15;51:1498-504 [[18402906](#)]